You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Moodys
Merck
AstraZeneca
Dow

Last Updated: April 9, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Evobrutinib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Evobrutinib?

Evobrutinib is an investigational drug.

There have been 8 clinical trials for Evobrutinib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2019.

The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and Multiple Sclerosis. The leading clinical trial sponsors are Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc., and Merck KGaA.

There are four US patents protecting this investigational drug and thirty international patents.

Recent Clinical Trials for Evobrutinib
TitleSponsorPhase
Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial TabletsMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)Merck KGaA, Darmstadt, GermanyPhase 3
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)EMD Serono Research & Development Institute, Inc.Phase 3

See all Evobrutinib clinical trials

Clinical Trial Summary for Evobrutinib

Top disease conditions for Evobrutinib
Top clinical trial sponsors for Evobrutinib

See all Evobrutinib clinical trials

US Patents for Evobrutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evobrutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Evobrutinib Australia 2012267491 2031-06-10   Start Trial
Evobrutinib Australia 2017235978 2031-06-10   Start Trial
Evobrutinib Brazil 112013030442 2031-06-10   Start Trial
Evobrutinib Canada 2833771 2031-06-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.